Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients
Recruiting
Phase 1
Phase 2
Interventional Study
Kidney Failure,Chronic
Anemia in End Stage Renal Disease
Depression Anxiety Disorder
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 46 (estimated)
- Sponsor
- Mansoura University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
People with severe kidney failure who need regular hemodialysis treatment often experience several health problems. These include anemia (low red blood cell count), issues with their bone health (sometimes called mineral and bone disease), and mental health challenges like depression and anxiety. They may also have problems with their nerves and muscles.
Roxadustat is a newer medicine, taken as a…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* The age of the patient is more than 18.
* Patients who are willing to sign informed consent.
* Patients with ESKD on chronic hemodialysis for more than 3 months.
Exclusion Criteria:
* Current pregnancy or lactation.
* Patients with pre-existing malignancy.
* patients with ps…
Contacts